NEW YORK (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a ...

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

Regeneron collaborates with Truveta to expand a genomic database, investing $119.5 million to enhance genetics-based healthcare research. Regeneron's $119.5 million investment in Truveta's Series ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Seventeen health systems are investing in a genomic database that could significantly drive down clinical costs. Truveta, a Washington-based software company, unveiled the Truveta Genome Project on ...

US health systems and Regeneron Genetics Center launch the Truveta Genome Project, a $320M initiative to sequence up to 10M ...

NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

Those data will join Regeneron’s existing DNA sequence-linked health care database of nearly 3 million people. Part of the company’s interest in joining the Truveta Genome Project was the ...